Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...
Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...
Investor's Business Daily on MSN
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
Across its portfolio, Regeneron brought in $3.75 billion in sales and adjusted earnings of $11.83 a share. Sales edged 1% ...
Regeneron has settled its patent dispute with Celltrion, giving the go-ahead for another biosimilar to its blockbuster eye drug Eylea (aflibercept) to hit the U.S. market in just over a year. | With ...
The bear phase in Regeneron (REGN) appears over. Shares bottomed at around $550 - $575 and jumped by around 12% to over $650 ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback